Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
Tanya Siddiqi(City Of Hope National Medical Center), David G. Maloney(Fred Hutch Cancer Center), Saad S. Kenderian(Mayo Clinic in Arizona), Danielle M. Brander(Duke University Health System), Kathleen Dorritie(UPMC Hillman Cancer Center), Jacob D. Soumerai(Massachusetts General Hospital), Peter A. Riedell(University of Chicago), Nirav N. Shah(Medical College of Wisconsin), Rajneesh Nath(Banner MD Anderson Cancer Center), Bita Fakhri(University of California, San Francisco), Deborah M. Stephens(Huntsman Cancer Institute), Shuo Ma(Northwestern University), Tatyana Feldman(Hackensack Meridian Health), Scott R. Solomon(Northside Hospital), Stephen J. Schuster(UPMC Hillman Cancer Center), Serena Perna(Bristol-Myers Squibb (United States)), Sherilyn A. Tuazon(Bristol-Myers Squibb (United States)), San-San Ou(Bristol-Myers Squibb (United States)), Eniko Papp(Bristol-Myers Squibb (United States)), Leanne Peiser(Bristol-Myers Squibb (United States)), Yizhe Chen(Bristol-Myers Squibb (United States)), William G. Wierda(The University of Texas MD Anderson Cancer Center)
Cited by 191Open Access